Beraprost for the treatment of intermittent claudication

Journal of the American College of Cardiology

Volumn 41, Issue 10, 2003, Pages 1687-1689

  Cooper, Leslie T ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; AS 103; BERAPROST; BUFLOMEDIL; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; NAFIDROFURYL; PENTOXIFYLLINE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; PROSTAVASIN; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DISABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LIMB ISCHEMIA; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; SMOKING CESSATION; STROKE; TREADMILL EXERCISE; TREATMENT OUTCOME; VASODILATATION; WALKING;

EID: 0037564103     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00308-5     Document Type: Editorial

References (22)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial occlusive disease in a defined population. Circulation 1985;71:510-5.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
3. Vogt M. Peripheral Arterial Disease: The Epidemiology and Burden of Disease. Hirsch A, editor. Elderly Women, in Primary Care Series: Peripheral Arterial Disease and Intermittent Claudication. Hillsborough, NJ: Excerpta Medica, 2001:157-61.
4. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 1997;2:221-6.
5. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. J Card Surg 1989;30:50-7.
6. Regensteiner J, Gardner A, Hiatt W. Exercise testing and exercise rehabilitation for patients with peripheral arterial disease: status in 1997. Vasc Med 1997;2:147-55.
7. Bacle G, Bogaerts H, Clement DL, Pannier R, Barbier F. Platelet activation during treadmill exercise in patients with chronic peripheral arterial disease. Thromb Haemost 1981;46:288.
8. Pernow B, Zetterquist S. Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstructions at different levels. Scand J Clin Lab Invest 1968;21:277-87.
9. Hiatt W, Nawaz D, Brass E. Carnitine metabolism during exercise in patients with peripheral vascular disease. J Appl Physiol 1987;62:2383-7.
10. Regensteiner J, Wolfel EE, Brass EP, et al. Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation 1993;87:413-21.
11. Tjon JA, Riemann LE. Treatment of intermittent claudication with pentoxifylline and cilostazol. Am J Health Syst Pharm 2001;58:485-93.
12. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30.
13. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet treatment, part II: Maintenance of vascular graft patency by antiplatelet therapy. BMJ 1994;309:159-68.
14. Belch J, McKay A, McArdle B, et al. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet 1983;8320:315-7.
15. 1 . Ann Intern Med 1999;130:412-21.
16. Dormandy J. Use of prostacyclin analogue iloprost in the treatment of patients with critical limb ischaemia. Therapie 1991;46:319-22.
17. 2 ) infusion to 108 patients with ischaemic peripheral vascular disease: phase II-open study. Prostaglandins Leukot Essent Fatty Acids 1991;42:9-14.
18. 1 pro-drug, in patients with intermittent claudication. Circulation 1997;95:2298-302.
19. 2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003;41:1679-86.
20. Demolis J, Robert A, Mouren M, Funck-Brentano C, Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Card Pharm 1993;22:711-6.
21. Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP. A dose-effect study of beraprost sodium in intermittent claudication. J Card Pharm 1996;27:788-93.
22. 2 analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000;102:426-31.